Conflicts of interests (COIs) for the MSIF Off-label treatments (MOLT) panel were independently assessed by the European Academy of Neurology (EAN) Ethics and Quality Task Force.
- EAN MOLT COI report December 2020
- EAN MOLT COI addendum March 2021
- MOLT update February 2022
- EAN MOLT COI letter February 2022
MSIF COI statement 2023
Multiple Sclerosis International Federation (MSIF) is an alliance of national multiple sclerosis (MS) organisations. MSIF receives income from a wide range of sources, including healthcare and other companies, individuals, member organisations, campaigns, foundations and trusts. Over the last 5 years, MSIF received funding from the following companies: BristolMyersSquibb, Sanofi, Merck, Viatris (formerly Mylan), Novartis, Biogen and Roche – all of which is publicly disclosed. Our independence and all our donations from the healthcare industry are governed by our healthcare policy. MSIF has not received any funding from industry for its access to medicines work in 2019, 2020, 2021 or 2022.